These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 27841828)

  • 1. Nivolumab in the Treatment of Refractory Pediatric Hodgkin Lymphoma.
    Foran AE; Nadel HR; Lee AF; Savage KJ; Deyell RJ
    J Pediatr Hematol Oncol; 2017 Jul; 39(5):e263-e266. PubMed ID: 27841828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nivolumab as salvage treatment in a patient with HIV-related relapsed/refractory Hodgkin lymphoma and liver failure with encephalopathy.
    Sandoval-Sus JD; Mogollon-Duffo F; Patel A; Visweshwar N; Laber DA; Kim R; Jagal MV
    J Immunother Cancer; 2017; 5():49. PubMed ID: 28642818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.
    Younes A; Santoro A; Shipp M; Zinzani PL; Timmerman JM; Ansell S; Armand P; Fanale M; Ratanatharathorn V; Kuruvilla J; Cohen JB; Collins G; Savage KJ; Trneny M; Kato K; Farsaci B; Parker SM; Rodig S; Roemer MG; Ligon AH; Engert A
    Lancet Oncol; 2016 Sep; 17(9):1283-94. PubMed ID: 27451390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nivolumab-induced cytokine-release syndrome in relapsed/refractory Hodgkin's lymphoma: a case report and literature review.
    Zhao L; Yang Y; Li W; Li T; Gao Q
    Immunotherapy; 2018 Aug; 10(11):913-917. PubMed ID: 30149764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful treatment of relapsed/refractory Hodgkins lymphoma with nivolumab in a heavily pretreated patient with progressive disease after both autologous and allogeneic stem cell transplantation.
    Aslan A; Aras T; Özdemir E
    Leuk Lymphoma; 2017 Mar; 58(3):754-755. PubMed ID: 27687237
    [No Abstract]   [Full Text] [Related]  

  • 7. PD-1 blockade induces remissions in relapsed classical Hodgkin lymphoma following allogeneic hematopoietic stem cell transplantation.
    Godfrey J; Bishop MR; Syed S; Hyjek E; Kline J
    J Immunother Cancer; 2017; 5():11. PubMed ID: 28239465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin Lymphoma.
    Kasamon YL; de Claro RA; Wang Y; Shen YL; Farrell AT; Pazdur R
    Oncologist; 2017 May; 22(5):585-591. PubMed ID: 28438889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful treatment with low-dose nivolumab in refractory Hodgkin lymphoma after allogeneic stem cell transplantation.
    Onizuka M; Kojima M; Matsui K; Machida S; Toyosaki M; Aoyama Y; Kawai H; Amaki J; Hara R; Ichiki A; Ogawa Y; Kawada H; Nakamura N; Ando K
    Int J Hematol; 2017 Jul; 106(1):141-145. PubMed ID: 28097534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report.
    Li H; Ma W; Yoneda KY; Moore EH; Zhang Y; Pu LL; Frampton GM; Molmen M; Stephens PJ; Li T
    J Hematol Oncol; 2017 Feb; 10(1):64. PubMed ID: 28245875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autoimmune hemolytic anemia after nivolumab treatment in Hodgkin lymphoma responsive to immunosuppressive treatment. A case report.
    Tardy MP; Gastaud L; Boscagli A; Peyrade F; Gallamini A; Thyss A
    Hematol Oncol; 2017 Dec; 35(4):875-877. PubMed ID: 27539158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Back to life with checkpoint inhibitors in Hodgkin lymphoma.
    Dada R; Zekri J
    J Oncol Pharm Pract; 2018 Mar; 24(2):139-142. PubMed ID: 28597713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy.
    Kazandjian D; Suzman DL; Blumenthal G; Mushti S; He K; Libeg M; Keegan P; Pazdur R
    Oncologist; 2016 May; 21(5):634-42. PubMed ID: 26984449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-related Refractory Hodgkin Lymphoma: A Case Report of Complete Response to Nivolumab.
    Chang E; Rivero G; Patel NR; Chiao EY; Lai S; Bajaj K; Mbue JE; Yellapragada SV
    Clin Lymphoma Myeloma Leuk; 2018 Feb; 18(2):e143-e146. PubMed ID: 29342442
    [No Abstract]   [Full Text] [Related]  

  • 15. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.
    Ansell SM; Lesokhin AM; Borrello I; Halwani A; Scott EC; Gutierrez M; Schuster SJ; Millenson MM; Cattry D; Freeman GJ; Rodig SJ; Chapuy B; Ligon AH; Zhu L; Grosso JF; Kim SY; Timmerman JM; Shipp MA; Armand P
    N Engl J Med; 2015 Jan; 372(4):311-9. PubMed ID: 25482239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nivolumab for the treatment of classical Hodgkin lymphoma after failure of autologous stem cell transplant and brentuximab.
    Villasboas JC; Ansell SM
    Expert Rev Anticancer Ther; 2016; 16(1):5-12. PubMed ID: 26577822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDG-PET in the evaluation of response to nivolumab in recurrent non-small-cell lung cancer.
    Higuchi M; Owada Y; Inoue T; Watanabe Y; Yamaura T; Fukuhara M; Hasegawa T; Suzuki H
    World J Surg Oncol; 2016 Sep; 14(1):238. PubMed ID: 27595749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent treatment advances in Hodgkin lymphoma: a concise review.
    Arulogun S; Hertzberg M; Gandhi MK
    Intern Med J; 2016 Dec; 46(12):1364-1369. PubMed ID: 26929077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma.
    Matsuki E; Younes A
    Curr Treat Options Oncol; 2016 Jun; 17(6):31. PubMed ID: 27193488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nivolumab induces impressive responses in relapsed/refractory classic Hodgkin lymphoma: Single institutional experience.
    Dada R; Zabani Y
    J Oncol Pharm Pract; 2019 Oct; 25(7):1586-1589. PubMed ID: 30253728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.